TY - JOUR
KW - Adult
KW - Female
KW - Hallucinogens/therapeutic use
KW - Humans
KW - Ibogaine/adverse effects/therapeutic use
KW - Male
KW - Opioid-Related Disorders/drug therapy
KW - Substance Withdrawal Syndrome/drug therapy
KW - Treatment Outcome
KW - Young Adult
KW - 18-methoxycoronaridine
KW - Ibogaine
KW - alkaloid
KW - Heroin
KW - noribogaine
KW - opioid use disorder
KW - Oxycodone
KW - prescription opioid
AU - Thomas Kingsley Brown
AU - Kenneth Alper
A1 - 
AB - BACKGROUND: Ibogaine is a monoterpene indole alkaloid used in medical and nonmedical settings for the treatment of opioid use disorder. Its mechanism of action is apparently novel. There are no published prospective studies of drug use outcomes with ibogaine. OBJECTIVES: To study outcomes following opioid detoxification with ibogaine. METHODS: In this observational study, 30 subjects with DSM-IV Opioid Dependence (25 males, 5 females) received a mean total dose of 1,540 +/- 920 mg ibogaine HCl. Subjects used oxycodone (n = 21; 70%) and/or heroin (n = 18; 60%) in respective amounts of 250 +/- 180 mg/day and 1.3 +/- 0.94 g/day, and averaged 3.1 +/- 2.6 previous episodes of treatment for opioid dependence. Detoxification and follow-up outcomes at 1, 3, 6, 9, and 12 months were evaluated utilizing the Subjective Opioid Withdrawal Scale (SOWS) and Addiction Severity Index Composite (ASIC) scores, respectively. RESULTS: SOWS scores decreased from 31.0 +/- 11.6 pretreatment to 14.0 +/- 9.8 at 76.5 +/- 30 hours posttreatment (t = 7.07, df = 26, p < 0.001). At 1-month posttreatment follow-up, 15 subjects (50%) reported no opioid use during the previous 30 days. ASIC Drug Use and Legal and Family/Social Status scores were improved relative to pretreatment baseline at all posttreatment time points (p < .001). Improvement in Drug Use scores was maximal at 1 month, and subsequently sustained from 3 to 12 months at levels that did not reach equivalence to the effect at 1 month. CONCLUSION: Ibogaine was associated with substantive effects on opioid withdrawal symptoms and drug use in subjects for whom other treatments had been unsuccessful, and may provide a useful prototype for discovery and development of innovative pharmacotherapy of addiction.
AD - a University of California , San Diego , CA , USA.; b Departments of Psychiatry and Neurology , New York University School of Medicine , New York , NY , USA.
BT - The American Journal of Drug and Alcohol Abuse
C5 - Measures; Opioids & Substance Use
CP - 1
CY - England
DO - 10.1080/00952990.2017.1320802
IS - 1
JF - The American Journal of Drug and Alcohol Abuse
LA - eng
M1 - Journal Article
N2 - BACKGROUND: Ibogaine is a monoterpene indole alkaloid used in medical and nonmedical settings for the treatment of opioid use disorder. Its mechanism of action is apparently novel. There are no published prospective studies of drug use outcomes with ibogaine. OBJECTIVES: To study outcomes following opioid detoxification with ibogaine. METHODS: In this observational study, 30 subjects with DSM-IV Opioid Dependence (25 males, 5 females) received a mean total dose of 1,540 +/- 920 mg ibogaine HCl. Subjects used oxycodone (n = 21; 70%) and/or heroin (n = 18; 60%) in respective amounts of 250 +/- 180 mg/day and 1.3 +/- 0.94 g/day, and averaged 3.1 +/- 2.6 previous episodes of treatment for opioid dependence. Detoxification and follow-up outcomes at 1, 3, 6, 9, and 12 months were evaluated utilizing the Subjective Opioid Withdrawal Scale (SOWS) and Addiction Severity Index Composite (ASIC) scores, respectively. RESULTS: SOWS scores decreased from 31.0 +/- 11.6 pretreatment to 14.0 +/- 9.8 at 76.5 +/- 30 hours posttreatment (t = 7.07, df = 26, p < 0.001). At 1-month posttreatment follow-up, 15 subjects (50%) reported no opioid use during the previous 30 days. ASIC Drug Use and Legal and Family/Social Status scores were improved relative to pretreatment baseline at all posttreatment time points (p < .001). Improvement in Drug Use scores was maximal at 1 month, and subsequently sustained from 3 to 12 months at levels that did not reach equivalence to the effect at 1 month. CONCLUSION: Ibogaine was associated with substantive effects on opioid withdrawal symptoms and drug use in subjects for whom other treatments had been unsuccessful, and may provide a useful prototype for discovery and development of innovative pharmacotherapy of addiction.
PP - England
PY - 2018
SN - 1097-9891; 0095-2990
SP - 24
EP - 36
EP - 
T1 - Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes
T2 - The American Journal of Drug and Alcohol Abuse
TI - Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes
U1 - Measures; Opioids & Substance Use
U2 - 28541119
U3 - 10.1080/00952990.2017.1320802
VL - 44
VO - 1097-9891; 0095-2990
Y1 - 2018
ER -